DrugPatentWatch Database Preview
Patent: 8,927,694
» See Plans and Pricing
Summary for Patent: 8,927,694
| Title: | Human serum albumin linkers and conjugates thereof |
| Abstract: | Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate. |
| Inventor(s): | McDonagh; Charlotte (Winchester, MA), Feldhaus; Michael (Grantham, NH), Huhalov; Alexandra (Cambridge, MA) |
| Assignee: | Merrimack Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 13/130,007 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,927,694
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | Start Trial | Merrimack Pharmaceuticals, Inc. (Cambridge, MA) | 2028-11-18 | RX | search | |
| Genentech | PERJETA | pertuzumab | VIAL; SINGLE-USE | 125409 | 001 | 2012-06-08 | Start Trial | Merrimack Pharmaceuticals, Inc. (Cambridge, MA) | 2028-11-18 | RX | search | |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 002 | 2004-02-26 | Start Trial | Merrimack Pharmaceuticals, Inc. (Cambridge, MA) | 2028-11-18 | RX | search | |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | Merrimack Pharmaceuticals, Inc. (Cambridge, MA) | 2028-11-18 | RX | search | |
| Genentech | HERCEPTIN | trastuzumab | VIAL; INTRAVENOUS | 103792 | 001 | 1998-09-25 | Start Trial | Merrimack Pharmaceuticals, Inc. (Cambridge, MA) | 2028-11-18 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 8,927,694
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 201008048 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2009126920 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2010059315 | Start Trial |
| United States of America | 2011059076 | Start Trial |
| United States of America | 2012003221 | Start Trial |
| United States of America | 2015191545 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
